Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 4934

1.

Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.

Niho S, Yoshida T, Akimoto T, Sakamaki K, Ono A, Seto T, Nishio M, Yamamoto N, Hida T, Okamoto H, Kurata T, Satouchi M, Goto K, Yamanaka T, Ohe Y.

Lung Cancer. 2020 Jan 10;141:64-71. doi: 10.1016/j.lungcan.2020.01.008. [Epub ahead of print]

PMID:
31955002
2.

Draft Genome Sequence of Rhodococcus aetherivorans JCM 14343T, a Bacterium Capable of Degrading Recalcitrant Noncyclic and Cyclic Ethers.

Inoue D, Nakazawa M, Yamamoto N, Sei K, Ike M.

Microbiol Resour Announc. 2020 Jan 16;9(3). pii: e01345-19. doi: 10.1128/MRA.01345-19.

3.

Catalytic Atroposelective Synthesis of N-Aryl Quinoid Compounds.

Vaidya SD, Toenjes ST, Yamamoto N, Maddox SM, Gustafson JL.

J Am Chem Soc. 2020 Jan 16. doi: 10.1021/jacs.9b12994. [Epub ahead of print]

PMID:
31944689
4.

Characteristics of Symptomatic Pulmonary Thromboembolism among Postoperative and Hospitalized Patients.

Yamamoto N, Unno N, Inuzuka K, Sano M, Saito T, Sugisawa R, Katahashi K, Yata T, Kayama T, Yamanaka Y.

Ann Vasc Dis. 2019 Dec 25;12(4):480-486. doi: 10.3400/avd.oa.19-00125.

5.

Kleptoprotein bioluminescence: Parapriacanthus fish obtain luciferase from ostracod prey.

Bessho-Uehara M, Yamamoto N, Shigenobu S, Mori H, Kuwata K, Oba Y.

Sci Adv. 2020 Jan 8;6(2):eaax4942. doi: 10.1126/sciadv.aax4942. eCollection 2020 Jan.

6.

Ligament Reconstruction for Recurrent Anterior Dislocation of the Radial Head.

Hatta T, Shinagawa K, Hayashi K, Hasegawa K, Miyasaka Y, Yamamoto N, Itoi E.

Case Rep Orthop. 2019 Dec 16;2019:6067312. doi: 10.1155/2019/6067312. eCollection 2019.

7.

Successful percutaneous treatment of recurrent post-infarction ventricular septal rupture using an Amplatzer duct occluder.

Ishiyama M, Kurita T, Ishiura J, Yamamoto N, Sugiura E, Ito H, Tada N, Fujimoto N, Ito M, Dohi K.

J Cardiol Cases. 2019 Sep 25;21(1):12-15. doi: 10.1016/j.jccase.2019.09.003. eCollection 2020 Jan.

8.

Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3.

Yoshioka H, Kato T, Okamoto I, Tanaka H, Hida T, Seto T, Kiura K, Tian Y, Azuma H, Yamamoto N.

Future Oncol. 2020 Feb;16(4):49-60. doi: 10.2217/fon-2019-0659. Epub 2020 Jan 10.

9.

Ground-glass opacity as a paradoxical reaction in miliary tuberculosis: A case report and review of the literature.

Tokuyama Y, Matsumoto T, Kusakabe Y, Yamamoto N, Aihara K, Yamaoka S, Mishima M.

IDCases. 2019 Dec 19;19:e00685. doi: 10.1016/j.idcr.2019.e00685. eCollection 2020.

10.

Silicon Nanowires for Intracellular Optical Interrogation with Subcellular Resolution.

Rotenberg MY, Elbaz B, Nair V, Schaumann EN, Yamamoto N, Sarma N, Matino L, Santoro F, Tian B.

Nano Lett. 2020 Jan 9. doi: 10.1021/acs.nanolett.9b04624. [Epub ahead of print]

PMID:
31904975
11.

Effectiveness of Lifestyle Intervention Using the Internet of Things System for Individuals with Early Type 2 Diabetes Mellitus.

Kato S, Ando M, Honda H, Yoshida Y, Imaizumi T, Yamamoto N, Maruyama S.

Intern Med. 2020;59(1):45-53. doi: 10.2169/internalmedicine.3150-19. Epub 2020 Jan 1.

12.

Exquisite Tumor Targeting by Salmonella A1-R in Combination with Caffeine and Valproic Acid Regresses an Adult Pleomorphic Rhabdomyosarcoma Patient-Derived Orthotopic Xenograft Mouse Model.

Igarashi K, Kawaguchi K, Zhao M, Kiyuna T, Miyake K, Miyake M, Nelson SD, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Higuchi T, Singh SR, Tsuchiya H, Hoffman RM.

Transl Oncol. 2019 Dec 30;13(2):393-400. doi: 10.1016/j.tranon.2019.10.005. [Epub ahead of print]

13.

Safety and Efficacy of Carbon-ion Radiotherapy Alone for Stage III Non-small Cell Lung Cancer.

Anzai M, Yamamoto N, Hayashi K, Nakajima M, Nomoto A, Ogawa K, Tsuji H.

Anticancer Res. 2020 Jan;40(1):379-386. doi: 10.21873/anticanres.13963.

PMID:
31892590
14.

PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.

Higuchi T, Yamamoto J, Sugisawa N, Tashiro Y, Nishino H, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.

Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):35-40. doi: 10.21873/cgp.20165.

15.

Impact of the ESM-1 Gene Expression on Outcomes in Stage II/III Gastric Cancer Patients Who Received Adjuvant S-1 Chemotherapy.

Kano K, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Maezawa Y, Aoyama T, Fujikawa H, Hiroshima Y, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Shiozawa M, Yukawa N, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T.

In Vivo. 2020 Jan-Feb;34(1):461-467. doi: 10.21873/invivo.11796.

PMID:
31882514
16.

Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study.

Murakawa M, Yamamoto N, Kamioka Y, Kamiya M, Kobayashi S, Ueno M, Morimoto M, Atsumi Y, Aoyama T, Tamagawa H, Yukawa N, Rino Y, Masuda M, Morinaga S.

In Vivo. 2020 Jan-Feb;34(1):347-353. doi: 10.21873/invivo.11780.

PMID:
31882498
17.

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).

Seto T, Azuma K, Yamanaka T, Sugawara S, Yoshioka H, Wakuda K, Atagi S, Iwamoto Y, Hayashi H, Okamoto I, Saka H, Mitsuoka S, Fujimoto D, Nishino K, Horiike A, Daga H, Sone T, Yamamoto N, Nakagawa K, Nakanishi Y.

J Clin Oncol. 2019 Dec 27:JCO1901494. doi: 10.1200/JCO.19.01494. [Epub ahead of print]

PMID:
31880966
18.

Essential structure of orexin 1 receptor antagonist YNT-707, part V: Structure-activity relationship study of the substituents on the 17-amino group.

Saitoh T, Seki K, Nakajima R, Yamamoto N, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Yanagisawa M, Nagase H.

Bioorg Med Chem Lett. 2020 Feb 1;30(3):126893. doi: 10.1016/j.bmcl.2019.126893. Epub 2019 Dec 17.

PMID:
31879208
19.

The process of bone regeneration from devitalization to revitalization after pedicle freezing with immunohistochemical and histological examination in rabbits.

Xu G, Yamamoto N, Nojima T, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Tsuchiya H.

Cryobiology. 2019 Dec 22. pii: S0011-2240(19)30289-5. doi: 10.1016/j.cryobiol.2019.12.002. [Epub ahead of print]

20.

[A Case of Pediatric C1 Dysplasia with Ruptured Aneurysm in Collateral Plexiform Arterial Network].

Mizuno A, Haraguchi K, Okada T, Endo O, Fujii K, Takayanagi K, Hiramatsu T, Yamamoto N.

No Shinkei Geka. 2019 Dec;47(12):1261-1267. doi: 10.11477/mf.1436204113. Japanese.

PMID:
31874947
21.

Integrative transcriptome analysis discloses the molecular basis of a heterogeneous fungal phytopathogen complex, Rhizoctonia solani AG-1 subgroups.

Yamamoto N, Wang Y, Lin R, Liang Y, Liu Y, Zhu J, Wang L, Wang S, Liu H, Deng Q, Li S, Li P, Zheng A.

Sci Rep. 2019 Dec 23;9(1):19626. doi: 10.1038/s41598-019-55734-2.

22.

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.

Yamamoto N, Mera T, Märten A, Hochmair MJ.

Adv Ther. 2019 Dec 20. doi: 10.1007/s12325-019-01187-y. [Epub ahead of print]

PMID:
31863283
23.

Cathodoluminescence Phase Extraction of the Coupling between Nanoparticles and Surface Plasmon Polaritons.

Sannomiya T, Konečná A, Matsukata T, Thollar Z, Okamoto T, García de Abajo FJ, Yamamoto N.

Nano Lett. 2020 Jan 8;20(1):592-598. doi: 10.1021/acs.nanolett.9b04335. Epub 2019 Dec 24.

PMID:
31855432
24.

Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.

Higuchi T, Han Q, Miyake K, Oshiro H, Sugisawa N, Tan Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.

Biochem Biophys Res Commun. 2019 Dec 12. pii: S0006-291X(19)32344-7. doi: 10.1016/j.bbrc.2019.12.024. [Epub ahead of print]

PMID:
31839218
25.

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takahashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y.

Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30678-3. doi: 10.1016/S1470-2045(19)30678-3. [Epub ahead of print]

PMID:
31838011
26.

Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth of High-Risk Neuroblastoma Patients.

Mon Thwin KK, Ishida T, Uemura S, Yamamoto N, San Lin K, Tamura A, Kozaki A, Saito A, Kishimoto K, Mori T, Hasegawa D, Kosaka Y, Nino N, Takafuji S, Iijima K, Nishimura N.

J Mol Diagn. 2019 Dec 16. pii: S1525-1578(19)30437-4. doi: 10.1016/j.jmoldx.2019.10.012. [Epub ahead of print]

27.

The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in Gliomas.

Ohba S, Murayama K, Kuwahara K, Pareira ES, Nakae S, Nishiyama Y, Adachi K, Yamada S, Sasaki H, Yamamoto N, Abe M, Mukherjee J, Hasegawa M, Pieper RO, Hirose Y.

Neurosurgery. 2019 Dec 13. pii: nyz524. doi: 10.1093/neuros/nyz524. [Epub ahead of print]

PMID:
31833548
28.
29.

DNA metabarcoding-based diet survey for the Eurasian otter (Lutra lutra): Development of a Eurasian otter-specific blocking oligonucleotide for 12S rRNA gene sequencing for vertebrates.

Kumari P, Dong K, Eo KY, Lee WS, Kimura J, Yamamoto N.

PLoS One. 2019 Dec 12;14(12):e0226253. doi: 10.1371/journal.pone.0226253. eCollection 2019.

30.

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors.

Doi T, Matsubara N, Kawai A, Naka N, Takahashi S, Uemura H, Yamamoto N.

Invest New Drugs. 2019 Dec 10. doi: 10.1007/s10637-019-00859-4. [Epub ahead of print]

PMID:
31820255
31.

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T.

Lung Cancer. 2020 Jan;139:195-199. doi: 10.1016/j.lungcan.2019.11.025. Epub 2019 Nov 28.

PMID:
31812890
32.

Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy.

Oneyama M, Sakamoto N, Oue N, Kimura Y, Hiroshima Y, Hashimoto I, Hara K, Maezawa Y, Kano K, Aoyama T, Fujikawa H, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Yukawa N, Shiozawa M, Yoshikawa T, Morinaga S, Rino Y, Masuda M, Miyagi Y, Yasui W, Oshima T.

Anticancer Res. 2019 Dec;39(12):6567-6573. doi: 10.21873/anticanres.13872.

PMID:
31810922
33.

Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.

Abe K, Yamamoto N, Domoto T, Bolidong D, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Inatani H, Aoki Y, Higuchi T, Taniguchi Y, Yonezawa H, Araki Y, Aiba H, Minamoto T, Tsuchiya H.

Cancer Sci. 2019 Dec 6. doi: 10.1111/cas.14271. [Epub ahead of print]

34.

Joint-preservation surgery for pediatric osteosarcoma of the knee joint.

Takeuchi A, Yamamoto N, Hayashi K, Matsubara H, Miwa S, Igarashi K, Tsuchiya H.

Cancer Metastasis Rev. 2019 Dec 5. doi: 10.1007/s10555-019-09835-z. [Epub ahead of print] Review.

PMID:
31807972
35.

First-in-human phase I study of E7090, a novel selective FGFR inhibitor, in patients with advanced solid tumors.

Koyama T, Shimizu T, Iwasa S, Fujiwara Y, Kondo S, Kitano S, Yonemori K, Shimomura A, Iizumi S, Sasaki T, Furuse J, Yamamoto N.

Cancer Sci. 2019 Dec 2. doi: 10.1111/cas.14265. [Epub ahead of print]

36.

Severe fever with thrombocytopenia syndrome complicated with subdural hematoma: A rare case and literature review.

Endo T, Yamamoto N, Inoue S, Yoshikane T, Fujisawa N, Imada T, Hattori S.

J Gen Fam Med. 2019 Sep 9;20(6):251-254. doi: 10.1002/jgf2.273. eCollection 2019 Nov.

37.

The plant-type phosphoenolpyruvate carboxylase Gmppc2 is developmentally induced in immature soy seeds at the late maturation stage: a potential protein biomarker for seed chemical composition.

Yamamoto N, Sugimoto T, Takano T, Sasou A, Morita S, Yano K, Masumura T.

Biosci Biotechnol Biochem. 2020 Mar;84(3):552-562. doi: 10.1080/09168451.2019.1696179. Epub 2019 Nov 27.

PMID:
31771419
38.

Rho Guanine Nucleotide Exchange Factors Regulate Horizontal Axon Branching of Cortical Upper Layer Neurons.

Sasaki K, Arimoto K, Kankawa K, Terada C, Yamamori T, Watakabe A, Yamamoto N.

Cereb Cortex. 2019 Nov 20. pii: bhz256. doi: 10.1093/cercor/bhz256. [Epub ahead of print]

PMID:
31768529
39.

Monitoring the health-related Sustainable Development Goals: lessons learned and recommendations for improved measurement.

Asma S, Lozano R, Chatterji S, Swaminathan S, de Fátima Marinho M, Yamamoto N, Varavikova E, Misganaw A, Ryan M, Dandona L, Minghui R, Murray CJL.

Lancet. 2020 Jan 18;395(10219):240-246. doi: 10.1016/S0140-6736(19)32523-1. Epub 2019 Nov 22. Review. No abstract available.

PMID:
31767190
40.

Effects of bilateral cochlear implants in children: Timing of second surgery and the significance of wearing bilateral cochlear implants in Japan.

Mori N, Yamaguchi S, Ishida A, Kondo K, Okano T, Ito J, Omori K, Yamamoto N.

Auris Nasus Larynx. 2019 Nov 22. pii: S0385-8146(19)30924-1. doi: 10.1016/j.anl.2019.11.001. [Epub ahead of print]

PMID:
31767153
41.

Persistent Renal Dysfunction in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.

Kurogi K, Ishii M, Sakamoto K, Komaki S, Marume K, Kusaka H, Yamamoto N, Arima Y, Yamamoto E, Kaikita K, Tsujita K.

J Am Heart Assoc. 2019 Dec 3;8(23):e014096. doi: 10.1161/JAHA.119.014096. Epub 2019 Nov 26.

42.

Active Cancer and Elevated D-Dimer Are Risk Factors for In-Hospital Ischemic Stroke.

Yamaguchi I, Kanematsu Y, Shimada K, Korai M, Miyamoto T, Shikata E, Yamaguchi T, Yamamoto N, Yamamoto Y, Kitazato KT, Okayama Y, Takagi Y.

Cerebrovasc Dis Extra. 2019 Nov 22;9(3):129-138. doi: 10.1159/000504163. [Epub ahead of print]

43.

Peripheral-Track and Central-Track Hill-Sachs Lesions: A New Concept of Assessing an On-Track Lesion.

Yamamoto N, Shinagawa K, Hatta T, Itoi E.

Am J Sports Med. 2020 Jan;48(1):33-38. doi: 10.1177/0363546519886319. Epub 2019 Nov 22.

PMID:
31756135
44.

Evolution of Aspergillus oryzae before and after domestication inferred by large-scale comparative genomic analysis.

Watarai N, Yamamoto N, Sawada K, Yamada T.

DNA Res. 2019 Nov 22. pii: dsz024. doi: 10.1093/dnares/dsz024. [Epub ahead of print]

PMID:
31755931
45.

High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1.

Maezawa Y, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Kano K, Aoyama T, Hiroshima Y, Yamada T, Yamamoto N, Ogata T, Ito H, Cho H, Shiozawa M, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T.

J Cancer Res Clin Oncol. 2020 Jan;146(1):75-86. doi: 10.1007/s00432-019-03087-8. Epub 2019 Nov 21.

46.

Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

Matsumoto Y, Sawa K, Fukui M, Oyanagi J, Yoshimoto N, Suzumura T, Watanabe T, Kaneda H, Mitsuoka S, Asai K, Kimura T, Yamamoto N, Hirata K, Koh Y, Kawaguchi T.

Lung Cancer. 2020 Jan;139:80-88. doi: 10.1016/j.lungcan.2019.10.029. Epub 2019 Nov 2.

PMID:
31751804
47.

Improved survival among patients enrolled in oncology phase 1 trials in recent decades.

Ebata T, Shimizu T, Koyama T, Shimomura A, Iwasa S, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Yamamoto N.

Cancer Chemother Pharmacol. 2019 Nov 19. doi: 10.1007/s00280-019-03992-2. [Epub ahead of print]

PMID:
31745590
48.

Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.

Shibaki R, Murakami S, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Kusumoto M, Yamamoto N, Ohe Y.

Cancer Immunol Immunother. 2020 Jan;69(1):15-22. doi: 10.1007/s00262-019-02431-8. Epub 2019 Nov 19.

PMID:
31745589
49.

Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.

Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, Tanaka M, Harutani Y, Yamagata N, Okuda Y, Furuta K, Sugimoto T, Teraoka S, Hayata A, Tokudome N, Ozawa Y, Mori K, Koh Y, Yamamoto N.

Oncologist. 2019 Nov 19. pii: theoncologist.2019-0299. doi: 10.1634/theoncologist.2019-0299. [Epub ahead of print]

50.

Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae.

Abe R, Hagiya H, Akeda Y, Yamamoto N, Ishii Y, Tomono K.

BMC Res Notes. 2019 Nov 9;12(1):740. doi: 10.1186/s13104-019-4779-x.

Supplemental Content

Loading ...
Support Center